135 related articles for article (PubMed ID: 37209540)
41. Cost-effectiveness and budget impact analyses of tisagenlecleucel in adult patients with relapsed or refractory diffuse large B-cell lymphoma from Singapore's private insurance payer's perspective.
Wang XJ; Wang YH; Li SCT; Gkitzia C; Lim ST; Koh LP; Lim FLWI; Hwang WYK
J Med Econ; 2021; 24(1):637-653. PubMed ID: 33904359
[TBL] [Abstract][Full Text] [Related]
42. Cost-Effectiveness Analysis of Anlotinib as Third- or Further-Line Treatment for Relapsed Small Cell Lung Cancer (SCLC) in China.
Gong J; Wan Q; Shang J; Qian X; Su D; Sun Z; Liu G
Adv Ther; 2021 Oct; 38(10):5116-5126. PubMed ID: 34417989
[TBL] [Abstract][Full Text] [Related]
43. Cost-Effectiveness of brexucabtagene autoleucel for relapsed/refractory mantle cell lymphoma.
Marchetti M; Visco C
Leuk Lymphoma; 2023; 64(8):1442-1450. PubMed ID: 37229538
[TBL] [Abstract][Full Text] [Related]
44. Cost-effectiveness of gilteritinib for relapsed/refractory
Pandya BJ; Qi CZ; Garnham A; Yang H; Shah MV; Zeidan AM
J Manag Care Spec Pharm; 2021 Oct; 27(10):1469-1481. PubMed ID: 34595955
[No Abstract] [Full Text] [Related]
45. Sugemalimab plus chemotherapy vs. chemotherapy for metastatic non-small-cell lung cancer: A cost-effectiveness analysis.
Liang X; Chen X; Li H; Liu X; Li Y
Front Public Health; 2023; 11():1054405. PubMed ID: 36923040
[TBL] [Abstract][Full Text] [Related]
46. Immunosuppressive therapy for progressive idiopathic membranous nephropathy: a cost-effectiveness analysis in China.
Xu W; Zhang Z; Li D; Dai W; Pan C; Guo M; Zhao Y; Cui X
BMC Health Serv Res; 2023 Apr; 23(1):361. PubMed ID: 37046255
[TBL] [Abstract][Full Text] [Related]
47. A Cost-effectiveness Analysis of Brentuximab Vedotin in Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma.
Hux M; Zou D; Ma E; Sajosi P; Engstrom A; Selby R; Benson E; Briggs A; Bonthapally V
J Health Econ Outcomes Res; 2017; 4(2):188-203. PubMed ID: 37661948
[No Abstract] [Full Text] [Related]
48. Cost-Effectiveness Analysis of Tisagenlecleucel for the Treatment of Pediatric and Young Adult Patients with Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia in Japan.
Wakase S; Teshima T; Zhang J; Ma Q; Watanabe Y; Yang H; Qi CZ; Chai X; Xie Y; Wu EQ; Igarashi A
Transplant Cell Ther; 2021 Mar; 27(3):241.e1-241.e11. PubMed ID: 33781519
[TBL] [Abstract][Full Text] [Related]
49. Lisocabtagene maraleucel in the treatment of relapsed/refractory large B-cell lymphoma.
St-Pierre F; Gordon LI
Future Oncol; 2023 Jan; 19(1):19-28. PubMed ID: 36651471
[TBL] [Abstract][Full Text] [Related]
50. Cost-effectiveness analysis of dasatinib versus imatinib in pediatric philadelphia chromosome-positive acute lymphoblastic leukemia patients in China.
Cao W; Yu Y; Qiu Y; Liu L; Zhang H; Shi L; Xiao Y; Jia L; Zhang R; Wang X
BMC Health Serv Res; 2022 Dec; 22(1):1580. PubMed ID: 36567324
[TBL] [Abstract][Full Text] [Related]
51. Cost-effectiveness of sintilimab plus chemotherapy versus chemotherapy alone as first-line treatment of locally advanced or metastatic oesophageal squamous cell carcinoma.
Liu L; Wang L; Chen L; Ding Y; Zhang Q; Shu Y
Front Immunol; 2023; 14():1092385. PubMed ID: 36756110
[TBL] [Abstract][Full Text] [Related]
52. The Cost-effectiveness of Pixantrone for Third/Fourth-line Treatment of Aggressive Non-Hodgkin's Lymphoma.
Muszbek N; Kadambi A; Lanitis T; Hatswell AJ; Patel D; Wang L; Singer JW; Pettengell R
Clin Ther; 2016 Mar; 38(3):503-15. PubMed ID: 26856929
[TBL] [Abstract][Full Text] [Related]
53. Cost-effectiveness of brentuximab vedotin compared with conventional chemotherapy for relapsed or refractory classic Hodgkin lymphoma in China.
Xie S; Sheng Y; Chuang LH; Wu J
Health Econ Rev; 2024 Jun; 14(1):38. PubMed ID: 38842725
[TBL] [Abstract][Full Text] [Related]
54. Cost-Effectiveness Analysis of CAR T-Cell Therapies vs Antibody Drug Conjugates for Patients with Advanced Multiple Myeloma.
Kapinos KA; Hu E; Trivedi J; Geethakumari PR; Kansagra A
Cancer Control; 2023; 30():10732748221142945. PubMed ID: 36651055
[TBL] [Abstract][Full Text] [Related]
55. Cost-effectiveness analysis of nivolumab versus placebo for relapsed malignant mesothelioma.
Lang W; Wei J; Jiang Q; Ai Q; Zhao X; Xiao L; He Y
Int J Clin Pharm; 2024 Feb; 46(1):158-165. PubMed ID: 37991664
[TBL] [Abstract][Full Text] [Related]
56. Cost-Effectiveness Analysis of Dabrafenib Plus Trametinib and Vemurafenib as First-Line Treatment in Patients with BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma in China.
Gao T; Liu J; Wu J
Int J Environ Res Public Health; 2021 Jun; 18(12):. PubMed ID: 34201096
[No Abstract] [Full Text] [Related]
57. The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.
Fox M; Mealing S; Anderson R; Dean J; Stein K; Price A; Taylor RS
Health Technol Assess; 2007 Nov; 11(47):iii-iv, ix-248. PubMed ID: 17999842
[TBL] [Abstract][Full Text] [Related]
58. Cost-Effectiveness Analysis of Frontline Polatuzumab-Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone and/or Second-Line Chimeric Antigen Receptor T-Cell Therapy Versus Standard of Care for Treatment of Patients With Intermediate- to High-Risk Diffuse Large B-Cell Lymphoma.
Vijenthira A; Kuruvilla J; Crump M; Jain M; Prica A
J Clin Oncol; 2023 Mar; 41(8):1577-1589. PubMed ID: 36315922
[TBL] [Abstract][Full Text] [Related]
59. Cost-utility analysis of inotuzumab ozogamicin for relapsed or refractory B cell acute lymphoblastic leukemia from the perspective of Taiwan's health care system.
Lee TY; Chen HY; Chen TY; Li SS; Fang WT; Wen YC; Lo YW; Ou HT
Eur J Health Econ; 2020 Sep; 21(7):1105-1116. PubMed ID: 32506280
[TBL] [Abstract][Full Text] [Related]
60. Cost-effectiveness analysis of niraparib maintenance therapy in Chinese patients with platinum-sensitive recurrent ovarian cancer.
Qiu Y; Zha J; Ma A; Zhou T
Gynecol Oncol; 2023 Jul; 174():175-181. PubMed ID: 37209503
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
